

NWJCC Routinely Commissioned Medicines List for Specialist Services

18/09/2026	Notice: We are currently reviewing our list of providers. If you require any additional information, please contact us directly at NWJCCblueteq@wales.nhs.uk . Please note this is a list of routine commissioned medicines by the NWJCC and is continually updated. As such, this list is not exhaustive at present.									
Medicine Generic Name	Indication	Reference	Age Range	Approval Mechanism	Initiation Form Status	Continuation Form Status	NWJCC Directorate	NWJCC Policy	Commissioned Providers	
Acoramidis	Treatment of transthyretin amyloidosis with cardiomyopathy	TA1121	18-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	In development	Royal Free London NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust	
Adalimumab (M4C)	Treatment of severe active Crohn's disease in children aged 2-5 years old	TA187	2-5 years	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital	
Adalimumab (M4C)	Treatment of severe active Crohn's disease in children aged 6-17 years old	TA187	6-17 years	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital	
Adalimumab (M4C)	Treatment of moderate to severe active ulcerative colitis after the failure of conventional therapy in children aged 2-5 years old	TA329	2-5 years	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital	
Adalimumab (M4C)	Treatment of moderate to severe active ulcerative colitis after the failure of conventional therapy in children aged 6-17 years old	TA329	6-17 years	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital	
Agalsidase alfa	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	AWMSG 1107	18-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust	
Agalsidase beta	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	AWMSG 12	18-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust	
Alglucosidase alfa	Long term enzyme replacement therapy in patients with a confirmed diagnosis of Pompe disease (acid α-glucosidase deficiency)	AWMSG 0224	0-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust	
Anakinra	Treatment of systemic juvenile idiopathic arthritis in people 8 months or older	TA685	8 months-17 years	Blueteq	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Great Ormond Street Hospital for Children NHS Foundation Trust Guy's and St. Thomas Hospital NHS Foundation Trust Royal Free London NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust	
Anhydrous sodium thiosulfate	Prevention of hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours	TA1034	1 month-17 years	Blueteq	Live	Not Applicable	Women & Children	PP5315	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Velindre NHS Trust	
Asfotase alfa	Treatment of paediatric-onset hypophosphatasia in babies, children, young people and adults	HST23	0-110 years	Blueteq	Live	Not Applicable	Women & Children	PP156	Birmingham Women's and Children's NHS Foundation Trust Manchester University NHS Foundation Trust Sheffield Teaching Hospitals NHS Foundation Trust Sheffield Children's NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust	
Ataluren	Treatment of Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene in people 2 years and over who can walk	HST22 / AWMSG 3911	2-17 years	Blueteq	Live	Live	Women & Children	PP118	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust	
Avalglucosidase alfa	Treatment of Pompe disease	TA821	0-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust	
Belimumab	Treatment of active antibody-positive systemic lupus erythematosus	TA752	0-17 years	Blueteq	Live	Live	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Children's NHS Foundation Trust Bristol University Hospitals Birmingham NHS Foundation Trust	
Belumosudil	Treatment of chronic graft versus host disease after 2 or more lines of systemic therapy	TA949	12-17 years	Blueteq	Live	Live	Women & Children	PP5301	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Great Ormond Street Hospital for Children NHS Foundation Trust Imperial College Healthcare NHS Trust Manchester University NHS Foundation Trust The Newcastle upon Tyne Hospitals NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust	
Berotrastat	Prevention of recurrent attacks of hereditary angioedema in people 12 years and over	TA738	12-110 years	Blueteq	Live	Live	Cancer and Blood	PP236	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust	
Birch bark extract	Treatment of skin wounds associated with dystrophic and junctional epidermolysis bullosa	HST28	6 months-110 years	Blueteq	Live	Live	Women & Children	PP5284	Birmingham Women's and Children's NHS Foundation Trust Great Ormond Street Hospital for Children NHS Foundation Trust Guy's and St Thomas' NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust	
Blinatumomab (M4C)	For the treatment of relapsed/refractory negative B-precursor acute lymphoblastic leukaemia in individuals up to 17 years of age	TA450/AWMSG 3769	0-17 years	Blueteq	Live	Not Applicable	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board	
Blinatumomab (M4C)	Treatment of patients in first complete haematological complete remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in CHLD patients.	TA589	1-17 years	Blueteq	Live	Not Applicable	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board	
Burosumab	Treatment of X-linked hypophosphataemia in adults	TA993	18-110 years	Blueteq	Live	Live	Women & Children	PP5177	Cardiff and Vale University Health Board The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust	
Burosumab	Treatment of X-linked hypophosphataemia in children and young people	HST8	1-17 years	Blueteq	Live	Live	Women & Children	PP5177	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board	
Canakinumab	Treatment of periodic fever syndromes: TRAPS, HIDS/MKD and PMF in people aged 2 years and older	Policy	2-110 years	Blueteq	Live	Live	Women & Children	PP228	Currently being confirmed with commissioning teams	
Cannabidiol	Adjuvant treatment of seizures associated with Dravet syndrome in people aged 2 years and older	TA614	2-17 years	Blueteq	Live	Live	Women & Children	PP5203	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board	
Cannabidiol	Adjuvant treatment of seizures associated with Lennox-Gastaut syndrome in people aged 2 years and older	TA615	2-17 years	Blueteq	Live	Live	Women & Children	PP5203	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board	

Cannabidiol	Adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older	TA873	2-17 years	Blueteq	Live	Live	Cancer and Blood	PP272	Currently being confirmed with commissioning teams
Cipaglucosidase alfa with Miglustat	Treatment of late-onset Pompe disease in adults	TA912	18-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Clesrovimab	To reduce the risk of respiratory syncytial virus (RSV) in infants with bronchopulmonary dysplasia (BPD) (also known as chronic lung disease of prematurity (CLD)) for the 26/27 season.	Green Book RSV	0-1 years	Blueteq	Live	Not Applicable	Women & Children	Green Book RSV	Alder Hey Children's NHS Foundation Trust Aneurin Bevan University Health Board Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Cwm Taf Morgannwg University Health Board Hwyel Dda University Health Board Powys Teaching Health Board Shrewsbury and Telford Hospital NHS Trust Swansea Bay University Health Board Wye Valley NHS Trust
Clesrovimab	To reduce the risk of respiratory syncytial virus (RSV) in infants with congenital heart disease (CHD) for the 26/27 season.	Green Book RSV	0-1 years	Blueteq	Live	Not Applicable	Women & Children	Green Book RSV	Alder Hey Children's NHS Foundation Trust Aneurin Bevan University Health Board Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Cwm Taf Morgannwg University Health Board Hwyel Dda University Health Board Powys Teaching Health Board Shrewsbury and Telford Hospital NHS Trust Swansea Bay University Health Board Wye Valley NHS Trust
Clesrovimab	To reduce the risk of respiratory syncytial virus (RSV) in infants with severe combined immunodeficiency syndrome (SCID) for the 26/27 season.	Green Book RSV	0-2 years	Blueteq	Live	Not Applicable	Women & Children	Green Book RSV	Alder Hey Children's NHS Foundation Trust Aneurin Bevan University Health Board Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Cwm Taf Morgannwg University Health Board Hwyel Dda University Health Board Powys Teaching Health Board Shrewsbury and Telford Hospital NHS Trust Swansea Bay University Health Board Wye Valley NHS Trust
Crivalimab	Treating Paroxysmal nocturnal haemoglobinuria	TA1019	18-110 years	Blueteq	Live	Live	Cancer and Blood	PP5152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueteq® forms.
Danicipan as an add-on treatment to a C5 inhibitor	Extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria	TA1010	18-110 years	Blueteq	Live	Live	Cancer and Blood	PP5152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueteq® forms.
Danicipan as an add-on treatment to a C5 inhibitor (H4C)	Extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria	TA1010	12-17 years	Blueteq	Live	In development	Cancer and Blood	H4C	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Leeds Teaching Hospitals NHS Trust Liverpool University Hospitals NHS Foundation Trust Manchester University NHS Foundation Trust
Dexrazoxane	Prevention of cardiotoxicity in children aged 16 years and under receiving high-dose anthracyclines or related drugs for the treatment of cancer	Policy	0-16 years	Blueteq	Live	Not Applicable	Women & Children	PP253	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Great Ormond Street Hospital For Children NHS Foundation Trust Manchester University NHS Foundation Trust Swansea Bay University Health Board Velindre University NHS Trust
Eculizumab	Treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH)	AWMSG 0509	0-110 years	Blueteq	Live	Live	Cancer and Blood	PP5152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueteq® forms.
Eculizumab	Treatment of atypical haemolytic uraemic syndrome	HST1	0-110 years	Blueteq	Live	Live	Welsh Kidney Network	PP5260	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Swansea Bay University Health Board
Eftasoctocog alfa	Treatment and prevention of bleeding episodes in haemophilia A in people 2 years and over	TA1051	2-110 years	Blueteq	Live	(1) In development	cancer and Blood	PP5327	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust Powys Teaching Health Board Swansea Bay University Health Board
Eltadocagene exuparovec	Treatment of aromatic L-amino acid decarboxylase deficiency	HST26	18 months-110 years	Blueteq	Live	Not applicable	Women & Children	PP281	Great Ormond Street Hospital For Children NHS Foundation Trust
Eliugustat	Treatment of Type 1 Gaucher disease	HST5	18-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Elosoflase alfa	Treatment of mucopolysaccharidosis type 4A in people of all ages	HST19	0-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Emicizumab	Prophylaxis in people with congenital haemophilia A without Factor VIII inhibitors (all ages)	Policy	0-110 years	Blueteq	Live	Live	Cancer and Blood	PP189	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board (<i>Continuation Only</i>) Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Emicizumab	Prophylaxis in people with congenital haemophilia A with Factor VIII inhibitors (all ages)	Policy	0-110 years	Blueteq	Live	Live	Cancer and Blood	PP5167	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board (<i>Continuation Only</i>) Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Emicizumab	Routine prophylaxis of bleeding episodes in patients with haemophilia A without factor VIII inhibitors who have moderate disease (FVIII = 1% and = 5%) with severe bleeding phenotype.	AWMSG 4742	0-110 years	Blueteq	Live	Live	Cancer and Blood	In development	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board (<i>Continuation Only</i>) Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Eplontersen	Treatment of hereditary transthyretin-related amyloidosis	TA1020	18-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	In development	Royal Free London NHS Foundation Trust
Everolimus	Adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC)	AWMSG 2142	2-17 years	Blueteq	Live	Live	Cancer and Blood	PP250	Currently being confirmed with commissioning teams

Everolimus	Treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery	AWMSG 1156	18-110 years	Blueteq	Live	Live	Cancer and Blood	PP274	Currently being confirmed with commissioning teams
Everolimus	Treatment of adult and paediatric patients with subependymal giant cell astrocytoma (SEGA) associated with TSC who require therapeutic intervention but are not amenable to surgery	AWMSG 1156	2-110 years	Blueteq	Live	In development	Cancer and Blood	PP273	Currently being confirmed with commissioning teams
Evinacumab	Treatment of homozygous familial hypercholesterolaemia in people 12 years and over	TA1002	12-110 years	Blueteq	Live	Live	Women & Children	PPS308	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Manchester University NHS Foundation Trust
Evinacumab (M4C)	Treatment of homozygous familial hypercholesterolaemia	TA1002	5-11 years	Blueteq	Live	Live	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Manchester University NHS Foundation Trust
Fenfluramine	Treatment of seizures associated with Dravet syndrome in people aged 2 and older	TA808	2-17 years	Blueteq	Live	Live	Women & Children	PPS203	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Fenfluramine	Treatment of seizures associated with Lennox-Gastaut syndrome in people aged 2 and older	TA1050	2-17 years	Blueteq	Live	Live	Women & Children	PPS203	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Galsulfase	Treatment of patients with long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis VI (MPS VI; N-acetylglucosamine 4-sulfatase deficiency; Maroteaux-Lamy syndrome)	AWMSG 0524	0-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Garadacimab	Prevention of recurrent attacks of hereditary angioedema in people 12 years and over	TA1101	12-110 years	Blueteq	Live	Live	Cancer and Blood	In development	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Givinostat	Treatment of Duchenne muscular dystrophy in people 6 years and over	TA1157	6-17 years	Blueteq	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
Givosiran	Treatment of acute hepatic porphyria	HST16	12-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP252	Cardiff and Vale University Health Board King's College Hospital NHS Foundation Trust
Glycerol Phenylbutyrate	Glycerol Phenylbutyrate for use as an adjunctive therapy for chronic management of patients with urea cycle disorders including deficiencies	AWMSG 1819	0-110 years	Blueteq	Live	Live	In development	In development	Currently being confirmed with commissioning teams
Home Parenteral Support	Treatment of adults (16 years and over) with type 2 and 3 intestinal failure	Policy	16-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	CP210	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Home Parenteral Support	Treatment of children (under 18 years) with type 2 and 3 intestinal failure	Policy	0-17 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	In development	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Imiglucerase	Treatment of Gaucher disease Type 1	Policy	18-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Imlifidase	Desensitisation treatment before kidney transplant in people with chronic kidney disease	TA809	18-110 years	Blueteq	Live	In development	Welsh Kidney Network	PPS256	Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Imlifidase (M4C)	Treatment of desensitisation treatment before kidney transplant in people with chronic kidney disease	TA809	Post-pubescent	Blueteq	Live	In development	Welsh Kidney Network	M4C	Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust
Infliximab (M4C)	Treatment of severe active Crohn's disease	TA187	6-17 years	Blueteq	Live	Live	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Children's Hospital
Infliximab (M4C)	Treatment of moderate to severe active ulcerative colitis after the failure of conventional therapy	TA329	6-17 years	Blueteq	Live	Live	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Children's Hospital
Iptacopan	Treatment of paroxysmal nocturnal haemoglobinuria in adults	TA1000	18-110 years	Blueteq	Live	Live	Cancer and Blood	PPS152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueteq® forms.
Lanadelumab	Prevention of recurrent attacks of hereditary angioedema	TA606	12-110 years	TBC	Live	Live	Cancer and Blood	In development	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Lanadelumab (M4C)	Prevention of recurrent attacks of hereditary angioedema	TA606	12-110 years	TBC	Live	Live	Cancer and Blood	M4C	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Laronidase	Treatment of mucopolysaccharidosis type I	AWMSG 180	0-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Leniolisib	Treatment of activated phosphoinositide 3-kinase delta syndrome in people 12 years and over	HST33	12-110 years	Blueteq	Live	Live	Cancer and Blood	In development	Currently being confirmed with commissioning teams
Lumasiran	Treatment of primary hyperoxaluria type 1 in people of all ages	HST25	0-110 years	Blueteq	Live	Live	Women & Children	PP277	Currently being confirmed with commissioning teams
Lutetium (177Lu) oxodotreotide	Treatment of unresectable or metastatic neuroendocrine tumours in adults	TA539	16-110 years	Blueteq	Live	Not applicable	Cancer and Blood	PP195	Currently being confirmed with commissioning teams

Marstacimab	Severe haemophilia A or moderately severe to severe haemophilia B in people 12 years and over	TA1073	12-110 years	Blueteq	Live	Live	Cancer and Blood	In development	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Mercaptamine bitartrate	Treatment of proven nephropathic cystinosis. Mercaptamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure	AWMSG 0922	0-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Higalastat	Treatment of Fabry disease	AWMSG 2122	12-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Miglustat	Treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease	AWMSG 0624	0-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Mirikizumab (M4C)	Treatment of moderately to severely active ulcerative colitis	TA925	2-17 years	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Mirikizumab (M4C)	Treatment of moderately to severely active Crohn's disease	TA1080	2-17 years	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Nirsevimab	To reduce the risk of respiratory syncytial virus (RSV) in infants with bronchopulmonary dysplasia (BPD) (also known as chronic lung disease of prematurity (CLD)) for the 26/27 season.	Green Book RSV	0-1 years	Blueteq	Live	Not Applicable	Women & Children	Green Book RSV	Alder Hey Children's NHS Foundation Trust Aneurin Bevan University Health Board Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Cwm Taf Morgannwg University Health Board Hypwel Eidda University Health Board Powys Teaching Health Board Shrewsbury and Telford Hospital NHS Trust Swansea Bay University Health Board Wye Valley NHS Trust
Nirsevimab	To reduce the risk of respiratory syncytial virus (RSV) in infants with congenital heart disease (CHD) for the 26/27 season.	Green Book RSV	0-1 years	Blueteq	Live	Not Applicable	Women & Children	Green Book RSV	Alder Hey Children's NHS Foundation Trust Aneurin Bevan University Health Board Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Cwm Taf Morgannwg University Health Board Hypwel Eidda University Health Board Powys Teaching Health Board Shrewsbury and Telford Hospital NHS Trust Swansea Bay University Health Board Wye Valley NHS Trust
Nirsevimab	To reduce the risk of respiratory syncytial virus (RSV) in infants with severe combined immunodeficiency syndrome (SCID) for the 26/27 season.	Green Book RSV	0-2 years	Blueteq	Live	Not Applicable	Women & Children	Green Book RSV	Alder Hey Children's NHS Foundation Trust Aneurin Bevan University Health Board Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Cwm Taf Morgannwg University Health Board Hypwel Eidda University Health Board Powys Teaching Health Board Shrewsbury and Telford Hospital NHS Trust Swansea Bay University Health Board Wye Valley NHS Trust
Nusinersen	Treatment of spinal muscular atrophy	TA1162	0-17 years	Blueteq	Live	Live	Women & Children	PP151	Alder Hey Children's NHS Foundation Trust Cardiff and Vale University Health Board
Ocrelizumab (M4C)	Treatment of primary progressive multiple sclerosis	TA585	Post-pubescent	Blueteq	Live	Live	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust
Ocrelizumab (M4C)	Treatment of relapsing-remitting multiple sclerosis	TA533	Post-pubescent	Blueteq	Live	Live	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust
Odevixibat	Treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older	HST17	6 months-17 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP249	Birmingham Women's and Children's NHS Foundation Trust King's College Hospital NHS Foundation Trust Leeds Teaching Hospitals NHS Trust
Patisiran	Treatment of hereditary transthyretin amyloidosis	HST10	16-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PPS187	Royal Free London NHS Foundation Trust
Pegcetacoplan	Treatment of Paroxysmal nocturnal haemoglobinuria	TA778	18-110 years	Blueteq	Live	In development	Cancer and Blood	PPS152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueteq® forms.
Pegunigalsidase alfa	Treatment of adults with Fabry disease	TA915	18-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Pegvalarginase	Treatment of arginase-1 deficiency in people 2 years and over	HST35	2-110 years	Blueteq	Live	Live	Women & Children	In development	Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board
Pembrolizumab	Treatment of relapsed/refractory classical Hodgkin lymphoma in patients 3-17 years of age who are stem cell transplant-ineligible and have failed brentuximab vedotin	TA967	3-17 years	Blueteq	Live	Not Applicable	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Pembrolizumab	Monotherapy for relapsed/refractory classical Hodgkin lymphoma in patients between 3-17 years of age who have NOT been treated with stem cell transplantation but never previously received brentuximab vedotin	TA772	3-17 years	Blueteq	Live	Not Applicable	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Pembrolizumab	Monotherapy for relapsed/refractory classical Hodgkin lymphoma in patients between 3-17 years of age who have NOT been previously treated with stem cell transplantation or brentuximab vedotin	TA772	3-17 years	Blueteq	Live	Not Applicable	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Ravulizumab	Treatment of paroxysmal nocturnal haemoglobinuria	TA698	18-110 years	Blueteq	Live	Live	Cancer and Blood	PPS152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueteq® forms.
Ravulizumab	Treatment of atypical haemolytic uraemic (aHUS) syndrome in adults and children	TA710	0-110 years	Blueteq	Live	Live	Welsh Kidney Network	PPS260	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board Swansea Bay University Health Board
Ravulizumab	Treatment of paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH)	AWMSG 4869	0-17 years	Blueteq	Live	Live	Women & Children	PPS152	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueteq® forms.

Risankizumab (M4C)	Treatment of moderately to severely active Crohn's disease	TA888	Post-pubescent	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Risdiplam	Treatment of spinal muscular atrophy in children and adults (NMOG commissioned in Paeds Only)	TA755	0-15 years	Blueteq	Live	Live	Women & Children	PP240	Currently being confirmed with commissioning teams
Ruxolitinib	Treatment of acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over	TA1054	12-110 years	Blueteq	Live	Not Applicable	Cancer and Blood	PP5292	Cardiff and Vale University Health Board Manchester University NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Ruxolitinib (M4C)	Treatment of acute graft versus host disease that responds inadequately to corticosteroids	TA1054	2-11 years	Blueteq	Live	Not Applicable	In development	M4C	Cardiff and Vale University Health Board Manchester University NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Sapropterin dihydrochloride	Treatment of hyperphenylalaninaemia (HPA) in phenylketonuria (PKU) and tetrahydrobiopterin (BH4) disorders	TA729	0-110 years	Blueteq	Live	Live	Women & Children	PP223	Alder Hey Children's NHS Foundation Trust Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Sebelipase alfa	Treatment of Wolman Disease	HST30	0-2 years	TBC	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Selpercatinib	Treatment of advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over	TA1038	12-16 years	Blueteq	Live	Not applicable	Women & Children	In development	Currently being confirmed with commissioning teams
Selumetinib	Treatment of symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over	HST20	3-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP267	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Guy's and St Thomas' NHS Foundation Trust Manchester University NHS Foundation Trust
Setmelanotide	Treatment obesity and hyperphagia in Bardet-Biedl syndrome (patients aged 6-17 years when treatment starts)	HST31	6-110 years	Blueteq	Live	Live	Women & Children	In development	Currently being confirmed with commissioning teams
Somapacitan	Treatment of growth hormone deficiency in people 3 to 17 years	TA1066	3-17 years	Blueteq	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Somatrogen	Growth disturbance in children and young people aged 3 years and over	TA863	3-17 years	Blueteq	Live	In development	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Somatropin	Treatment of growth failure in children	TA188	0-17 years	Blueteq	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Tafamidis	Treatment of transthyretin amyloidosis with cardiomyopathy in adults	TA984	16-110 years	Blueteq	Live	Live	Cardiac	In development	Royal Free London NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Teduglutide	Treatment of Short bowel syndrome in people 1 year and above	TA804	1-110 years	Blueteq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP265	Alder Hey Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Teriflunomide	Treatment of relapsing-remitting multiple sclerosis in children aged 10-17 years	TA303 / 4033	10-17 years	Blueteq	Live	Live	Women & Children	NA	Alder Hey Children's NHS Foundation Trust Cardiff and Vale University Health Board
Tofacitinib	Treatment of Juvenile idiopathic arthritis	TA735	2-17 years	Blueteq	Live	Live	Women & Children	PP229	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Great Ormond Street Hospital for Children NHS Foundation Trust Guy's and St. Thomas Hospital NHS Foundation Trust Royal Free London NHS Foundation Trust University Hospitals Bristol NHS Foundation Trust
Upadacitinib (M4C)	Treatment of moderately to severely active ulcerative colitis	TA856	12-17 years	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Upadacitinib (M4C)	Treatment of previously treated moderately to severely active Crohn's disease	TA905	12-17 years	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Ustekinumab	Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children	OW25	6-17 years	Blueteq	Live	Live	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Vamorolone	Treatment of Duchenne muscular dystrophy in people 4 years and over.	TA1031	4-17 years	Blueteq	Live	Live	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust
Vedolizumab	Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children	OW24	6-17 years	Blueteq	Live	Live	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Velaglutrase alfa	Treatment of Type 1 Gaucher disease	AWH56 1214	18-110 years	Blueteq	Live	Live	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Volanesorsen	Treatment of Familial chylomicronaemia syndrome in adults	HST13	18-110 years	Blueteq	Live	Live	Women & Children	PP217	Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board
Volanesorsen (M4C)	Treatment of Familial chylomicronaemia syndrome in adults	HST13	16-110 years	Blueteq	Live	Not applicable	Women & Children	M4C	Betsi Cadwaladr University Health Board Cardiff and Vale University Health Board
Vonicog alfa	Treatment and prevention of bleeding in adults and children with von Willebrand disease	OW19	0-110 years	Blueteq	Live	Live	Cancer and Blood	PP215	Alder Hey Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust

Voretigene neparovec	Treatment of Inherited retinal dystrophies caused by RPE65 gene mutations in adults and children	HST11	16-110 years	Blueqeq	Live	In development	Cardiac	PP196	Great Ormond Street Hospital For Children NHS Foundation Trust Greater Manchester Mental Health NHS Foundation Trust
Vutrisiran	Treatment of transthyretin amyloidosis with cardiomyopathy	TA1115	18-110 years	Blueqeq	Live	Live	Cardiac	In development	Royal Free London NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Vutrisiran	Treatment of hereditary transthyretin-related amyloidosis	TA868	18-110 years	Blueqeq	Live	Live	Neurosciences, Complex Conditions & Rare Diseases	PP187	Royal Free London NHS Foundation Trust
Atidarsagene autotemcel	Treatment of metachromatic leukodystrophy in children	HST18	0-17 years	Blueqeq	Live (a+b+c)	Not applicable	Women & Children	PP257	Greater Manchester Mental Health NHS Foundation Trust
Etranacogene dezaparovec	Treatment of moderately severe or severe haemophilia B	TA989	18-110 years	Blueqeq	Live a+b+c	(1) In development	Cancer and Blood	In development	Currently being confirmed with commissioning teams
Exagamglogene autotemcel	Treatment of transfusion-dependent beta-thalassemia in people 12 years and over	TA1003	12-110 years	Blueqeq	Live a+b+c	Not Applicable	Cancer and Blood	In development	Imperial College Healthcare NHS Trust Manchester University NHS Foundation Trust University College London Hospitals NHS Foundation Trust
Exagamglogene autotemcel	Treatment of severe sickle cell disease in people 12 years and over	TA1044	12-110 years	Blueqeq	Live a+b+c	Not Applicable	Cancer and Blood	In development	Imperial College Healthcare NHS Trust Manchester University NHS Foundation Trust University College London Hospitals NHS Foundation Trust
Avapritinib (M4C)	Treatment of advanced systemic mastocytosis	TA1012	Post-pubescent	Prior Approval	Not Applicable	Not Applicable	Women & Children	M4C	Currently being confirmed with commissioning teams
Belzutifan (M4C)	Treatment of tumours associated with von Hippel-Lindau disease	TA1011	Post-pubescent	Prior Approval	Not Applicable	Not Applicable	Cancer and Blood	M4C	Currently being confirmed with commissioning teams
Elafibranor (M4C)	Treatment of previously treated primary biliary cholangitis	TA1016	Post-pubescent	Prior Approval	Not Applicable	Not Applicable	Women & Children	M4C	Currently being confirmed with commissioning teams
Natlizumab (M4C)	Treatment of highly active relapsing-remitting multiple sclerosis after disease-modifying therapy	TA1126	In development	TBC	Not Applicable	Not Applicable	Women & Children	M4C	Currently being confirmed with commissioning teams
Strimvelis	Treatment of adenosine deaminase deficiency-severe combined immunodeficiency	HST7	0-65 years	Prior Approval	Not Applicable	Not Applicable	Cancer and Blood	In development	Ospedale San Raffaele (Milan, Italy)
Vanzacaftor-tezacaftor-deutivacaftor	Treatment of cystic fibrosis with an F508del mutation in the CFTR gene in people 6 years and over	TA1085	6-110 years	N/A	Not Applicable	Not Applicable	Cardiac	PP198	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool Heart and Chest Hospital NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust University Hospitals of North Midlands NHS Trust
Venetoclax with obinutuzumab (M4C)	Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia	TA1119	Post-pubescent	Prior Approval	Not Applicable	Not Applicable	In development	M4C	Currently being confirmed with commissioning teams
Agalsidase alfa (M4C)	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	M4C Policy	7-18 years	TBC	(1) In development	(1) In development	Women & Children	M4C	Cardiff and Vale University Health Board Manchester University NHS Foundation Trust
Agalsidase beta (M4C)	Long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease (α-galactosidase A deficiency)	M4C Policy	8-18 years	TBC	(1) In development	(1) In development	Women & Children	M4C	Cardiff and Vale University Health Board Manchester University NHS Foundation Trust
Ambrisentan	Treatment of pulmonary arterial hypertension (PAH)	AWMSG 4819	8-110 years	TBC	(1) In development	(1) In development	Cardiac	In development	Currently being confirmed with commissioning teams
Bevacizumab	Treatment of vestibular schwannoma in neurofibromatosis type 2	Policy	0-110 years	TBC	(1) In development	(1) In development	Neurosciences, Complex Conditions & Rare Diseases	CP254	Cambridge University Hospitals NHS Foundation Trust Manchester University Hospitals NHS Foundation Trust Guy's & St Thomas' NHS Foundation Trust Oxford University Hospital NHS Trust
Blinatumomab	Treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia (ALL) which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation	AWMSG 0519	1-17 years	Blueqeq	(1) In development	(1) In development	In development	add to policy tracker	Currently being confirmed with commissioning teams
Brentuximab (M4C)	Brentuximab-naïve relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option in CHLD patients Likely 12-17 years	TA524	12-17 years	Blueqeq	(1) In development	(1) In development	Women & Children	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board
Brivaracetam	Treatment of patients with refractory epilepsy, who remain uncontrolled with, or are intolerant to, other adjunctive anti-epileptic medicines, within its licensed indication as adjunctive therapy in the treatment of partial-onset seizures (POS) with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy	AWMSG 4614	2-17 years	Blueqeq	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
C1 esterase inhibitor	Prophylactic treatment of hereditary angioedema (HAE)	Policy	In development	Blueqeq	(1) In development	(1) In development	Cancer and Blood	In development	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Certolizumab pegol (M4C)	Treatment of active psoriatic arthritis after inadequate response to DMARDs	TA445	Post-pubescent	Prior Approval	(1) In development	(1) In development	Women & Children	M4C	Currently being confirmed with commissioning teams
Dabrafenib + trametinib	Treatment of BRAF V600E mutation-positive glioma in children and young people aged 1 year and over	TA977	1-17 years	Blueqeq	(1) In development	(1) In development	Women & Children	In development	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Dasatinib	Treatment of paediatric patients weighing ≥ 10 kg with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (Ph+CM-CP) or Ph+CM-CP resistant or intolerant to prior therapy including imatinib	AWMSG 0319	0-17 years	Blueqeq	(1) In development	(1) In development	In development	add to policy tracker	Currently being confirmed with commissioning teams

Defibrotide	Treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.	AWMSG 0515	In development	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
Dinutuximab beta	Treatment of neuroblastoma	TA538	1-17 years	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
Donidorsen	Preventing recurrent attacks of hereditary angioedema (HAE) in people 12 years and over	TA1183	12-110 years	Blueteq	(1) In development	(1) In development	Cancer and Blood	In development	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Eplontersen (M4C)	Treatment of hereditary transthyretin-related amyloidosis	TA1020	Post-pubescent	TBC	(1) In development	(1) In development	Neurosciences, Complex Conditions & Rare Diseases	In development	Royal Free London NHS Foundation Trust
Glofitamab with gemcitabine and oxaliplatin (M4C)	Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma	TA1113	In development	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
Golimumab (M4C)	Treatment of psoriatic arthritis	TA220	Post-pubescent	Prior Approval	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
Guselkumab	Treatment of moderately to severely active ulcerative colitis	TA1094	Post-pubescent	TBC	(1) In development	(1) In development	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Guselkumab	Treatment of previously treated moderately to severely active Crohn's disease	TA1095	Post-pubescent	TBC	(1) In development	(1) In development	Women & Children	In development	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Holoclax	Treatment of limbal stem cell deficiency after eye burns	TA467	In development	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
Hydrocortisone	Treatment of congenital adrenal hyperplasia in adolescents aged 12 years and older and in adults	AWMSG 3017	12-17 years	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
Icatibant	Treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency	AWMSG 0818	2-110 years	Blueteq	(1) In development	(1) In development	Cancer and Blood	In development	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool University Hospitals NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust
Ipilimumab	Treatment of advanced (unresectable or metastatic) melanoma in adolescents	AWMSG 1818	12-17 years	TBC	(1) In development	(1) In development	Women & Children	add to policy tracker	Currently being confirmed with commissioning teams
Iptacopan (M4C)	Treatment of paroxysmal nocturnal haemoglobinuria in adults	TA1000	Post-pubescent	TBC	(1) In development	(1) In development	Cancer and Blood	M4C	Please note that Haematologists in local Health Boards may prescribe this drug for PNH under the advice of the PNH National Service. This will include having access to complete the appropriate Blueteq® forms.
Larotrectinib	Treatment NTRK fusion-positive solid tumours	TA630	0-17 years	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
Letermovir	Prevention of cytomegalovirus disease after a stem cell transplant	TA591	18-110 years	Blueteq	(1) In development	(1) In development	Cancer and Blood	In development	Cardiff and Vale University Health Board Imperial College Healthcare NHS Trust Manchester University NHS Foundation Trust Sheffield Teaching Hospitals NHS Foundation Trust The Christie NHS Foundation Trust The Clatterbridge Cancer Centre NHS Foundation Trust The Newcastle Upon Tyne Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Letermovir (M4C)	Prevention of cytomegalovirus disease after a stem cell transplant (>56kg)	TA591	0-17 years	Blueteq	(1) In development	(1) In development	Women & Children	M4C	Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Manchester University NHS Foundation Trust The Clatterbridge Cancer Centre NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Lisocabtagene maraleucel	Treatment of relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment	TA1159	18-110 years	TBC	(1) In development	(1) In development	Cancer and Blood	In development	Birmingham and Solihull Mental Health NHS Foundation Trust Cardiff and Vale University Health Board King's College Hospital NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Mifamurtide	Treatment of osteosarcoma	TA235	2-17 years	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
Mirdametinib	Treatment symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 in people 2 to 17 years	TA1192	2-17 years	TBC	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
Nitisinone	Treatment of adult patients with alkaptonuria	AWMSG 2322	18-110 years	TBC	(1) In development	(1) In development	Neurosciences, Complex Conditions & Rare Diseases	In development	Currently being confirmed with commissioning teams
Nivolumab + ipilimumab (M4C)	Treatment of advanced melanoma	TA400	12-17 years	Blueteq	(1) In development	(1) In development	Women & Children	M4C	Currently being confirmed with commissioning teams
Nivolumab-relatlimab	For untreated unresectable or metastatic melanoma	TA950	12-17 years	Blueteq	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
Risankizumab (M4C)	Treatment of moderately to severely active ulcerative colitis	TA998	Post-pubescent	TBC	(1) In development	(1) In development	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Childrens Hospital
Rituximab / Eculizumab	Rituximab and eculizumab for the prevention and management of delayed haemolytic transfusion reactions and hyperhaemolysis in people with haemoglobinopathies	Policy	0-110 years	TBC	(1) In development	(1) In development	Cancer and Blood	PP5237	Currently being confirmed with commissioning teams
Romiplostim	Treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to < 18 years who are refractory to other treatments	AWMSG 0119	1-17 years	Blueteq	(1) In development	(1) In development	Cancer and Blood	In development	Currently being confirmed with commissioning teams

Ruxolitinib	Treatment of chronic graft versus host disease that responds inadequately to corticosteroids in people 12 years and over	TA840	12-17 years	TBC	(1) In development	(1) In development	cancer and Blood	In development	Currently being confirmed with commissioning teams
Ruxolitinib (M4C)	Treatment of chronic graft versus host disease that responds inadequately to corticosteroids	TA840	2-11 years	Blueteq	(1) In development	(1) In development	In development	M4C	Currently being confirmed with commissioning teams
Secukinumab (M4C)	Treatment of active psoriatic arthritis after inadequate response to DMARDs	TA445	6-17 years	TBC	(1) In development	(1) In development	Women & Children	M4C	Currently being confirmed with commissioning teams
Selexipag	Long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II-III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies	AWMSG 700	18-110 years	TBC	(1) In development	(1) In development	Cardiac	PP105	Currently being confirmed with commissioning teams
Selpercatinib	Treatment of advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over	TA1039	12-16 years	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
Selumetinib (M4C)	Treatment of symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 1-2 years	HST20	1-2 years	Blueteq	(1) In development	(1) In development	Neurosciences, Complex Conditions & Rare Diseases	M4C	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Guy's and St Thomas' NHS Foundation Trust Manchester University NHS Foundation Trust
Setmelanotide	Treating obesity caused by LEPR or POMC deficiency	HST1	6-110 years	TBC	(1) In development	(1) In development	Women & Children	In development	Currently being confirmed with commissioning teams
Talimogene laherparepvec	Treatment of unresectable metastatic melanoma	TA410	0-110 years	TBC	(1) In development	(1) In development	Cancer and Blood	In development	Currently being confirmed with commissioning teams
Talquetamab (M4C)	Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments	TA1114	Post-pubescent	Prior Approval	(1) In development	(1) In development	In development	M4C	Currently being confirmed with commissioning teams
Velmanase alfa	Treatment of alpha-mannosidosis in people under 18 years and in people who turn 18 while on treatment	HST29	0-17 years	TBC	(1) In development	(1) In development	Women & Children	CP55	Betsi Cadwaladr University Health Board Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Northern Care Alliance NHS Foundation Trust
Vorsidenib	Treatment of astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over	TA1147	12-17 years	Blueteq	(1) In development	(1) In development	In development	In development	Currently being confirmed with commissioning teams
Tofacitinib (M4C)	Treatment of moderately to severely active ulcerative colitis in children	TA547	2-17 years	Blueteq	Live	Live	Women & Children	M4C	Cardiff and Vale University Health Board Alder Hey Children's Hospital
Axicabtagene ciloleucel	Treatment of diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies	TA872	18-110 years	Blueteq	Live a+b	Not applicable	Cancer and Blood	CP175	Cardiff and Vale University Health Board King's College Hospital NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Axicabtagene ciloleucel	Treatment of relapsed or refractory diffuse large B-cell lymphoma after first-line chemotherapy	TA895	18-110 years	Blueteq	Live a+b	Not applicable	Cancer and Blood	In development	Cardiff and Vale University Health Board King's College Hospital NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Brexucabtagene autoleucel	Treatment of relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over	TA893	26-110 years	Blueteq	Live a+b	Not applicable	Cancer and Blood	In development	King's College Hospital NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Brexucabtagene (Formerly KTE-119)	Treatment of Relapsed or refractory mantle cell lymphoma	TA677	16-110 years	Blueteq	Live a+b	Not applicable	Cancer and Blood	In development	Cardiff and Vale University Health Board King's College Hospital NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Lisocabtagene maraleucel	Treatment of relapsed or refractory large B-cell lymphoma after first-line chemotherapy when a stem cell transplant is suitable	TA1048	18-110 years	Blueteq	Live a+b	Not Applicable	Cancer and Blood	In development	Birmingham and Solihull Mental Health NHS Foundation Trust Cardiff and Vale University Health Board King's College Hospital NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Obecabtagene autoleucel	Treatment of elapsed/refractory Philadelphia negative or positive B cell precursor acute lymphoblastic leukaemia in patients aged 26 years and older	TA1116	26-110 years	Blueteq	Live a+b	Not Applicable	Cancer and Blood	In development	King's College Hospital NHS Foundation Trust The Christie NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Onasemnogene asparovvec	Treatment of Spinal muscular atrophy type 1	HST15	0-12 months	Blueteq	Live a+b	Not applicable	Women & Children	In development	Currently being confirmed with commissioning teams
Onasemnogene asparovvec	Treatment of presymptomatic spinal muscular atrophy	HST24	0-12 months	Blueteq	Live a+b	Not applicable	Women & Children	In development	Currently being confirmed with commissioning teams
Tisagenlecleucel-T	Treatment of Relapsed or refractory B-cell acute lymphoblastic leukaemia in people up to 25 years	TA554	0-25 years	Blueteq	Live a+b	Not applicable	Cancer and Blood	PP185	Great Ormond Street Hospital for Children NHS Foundation Trust Manchester University NHS Foundation Trust The Christie NHS Foundation Trust The Clatterbridge Cancer Centre NHS Foundation Trust The Newcastle Upon Tyne Hospitals NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust
Ivacaftor-tezacaftor-efexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor	Treatment of cystic fibrosis	TA988	2-110 years	N/A	Not applicable	Not applicable	Cardiac	PP198	Alder Hey Children's NHS Foundation Trust Birmingham Women's and Children's NHS Foundation Trust Cardiff and Vale University Health Board Liverpool Heart and Chest Hospital NHS Foundation Trust Manchester University NHS Foundation Trust University Hospitals Birmingham NHS Foundation Trust University Hospitals Bristol and Weston NHS Foundation Trust University Hospitals of North Midlands NHS Trust